Angiosarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Angiosarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
Angiosarcoma is a rare type of cancer that that develops in the inner lining of the blood and lymph vessels and is linked to a gene called POTI. Angiosarcoma appears as a bruise-like lesion that grows over time. Once metastatic, it becomes difficult to treat and the survival rate drops to 12-33%.
The Angiosarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Angiosarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Angiosarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 43 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Angiosarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Angiosarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Angiosarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncActuate Therapeutics Inc
Agenus Inc
Amgen Inc
ANTUREC Pharmaceuticals GmbH
AstraZeneca Plc
Athenex Inc
BioInvent International AB
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Centrymed Pharmaceutical Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Co-D Therapeutics Inc
Curadev Pharma Pvt Ltd
DAE HWA Pharmaceutical Co Ltd
Diakonos Research Ltd
Eisai Co Ltd
Elevar Therapeutics Inc
F. Hoffmann-La Roche Ltd
Immutep Ltd
IMVAQ Therapeutics Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Merck KGaA
Moleculin Biotech Inc
Nano Mrna Co Ltd
NKGen Biotech Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Shanghai Affinity Biopharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Stella Pharma Corporation
Takeda Pharmaceutical Co Ltd
Texas Tech University Health Sciences Center
Tohoku University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Angiosarcoma reports